ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection) (RE-VIEW)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01722045
Recruitment Status : Completed
First Posted : November 6, 2012
Results First Posted : December 22, 2017
Last Update Posted : December 22, 2017
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

Brief Summary:
This is a phase 4, open-label, single arm, multicenter, clinical study in patients with neovascular AMD designed to evaluate the efficacy and safety of Intravitreal Aflibercept Injection (IAI) administered over 2 years , and to provide clinical information from the first year in the trial evaluating the adverse effects, if any, on the corneal endothelium following administration of IAI.

Condition or disease Intervention/treatment Phase
Age - Related Macular Degeneration (AMD) Drug: Intravitreal Aflibercept Injection (IAI) Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 154 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration
Study Start Date : November 2012
Actual Primary Completion Date : September 2015
Actual Study Completion Date : September 2015

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: Open label IAI Drug: Intravitreal Aflibercept Injection (IAI)



Primary Outcome Measures :
  1. Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score From Baseline to Week 100 - Last Observation Carried Forward (LOCF) [ Time Frame: Baseline to Week 100 ]
    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.


Secondary Outcome Measures :
  1. Percentage of Participants Whose Optical Coherence Tomography (OCT) Status Was "Dry" at Week 52 and at Week 100 (LOCF) [ Time Frame: Baseline to Week 100 ]
    Retinal fluid status was evaluated using spectral domain OCT on the study eye at every study visit. Last observation carried forward (LOCF) method was used to impute missing data.

  2. Percentage of Participants Who Gained ≥15 ETDRS Letters Compared With Baseline at Week 52 and Week 100 (LOCF) [ Time Frame: At week 52 and At week 100 ]
    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. LOCF approach was used if any ETDRS letter score was missed after start of treatment, but baseline data were not carried forward. No formal statistical analyses were performed.

  3. Change From Baseline in Best Corrected Visual Acuity Score Through Week 52 (LOCF) [ Time Frame: Baseline to Week 52 ]
    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.

  4. Percentage of Participants Who Gained ≥0, ≥5, ≥10, or ≥30 Letters From Baseline in BCVA Through Week 100 (LOCF) [ Time Frame: Baseline to Week 100 ]
    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.

  5. Percentage of Patients Who Lost >0, ≥5, ≥10, or ≥15 Letters From Baseline in BCVA Through Week 100 (LOCF) [ Time Frame: Baseline to Week 100 ]
    Visual function of the study eye was assessed at a distance of 4 meters at every study visit using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better functioning.


Other Outcome Measures:
  1. Percent Change From Baseline in Corneal Endothelial Cell Density (ECD) at Week 24 and Week 52 in the Study Eye and the Fellow Eye - Endothelial Cell Density Evaluable Set (EES) [ Time Frame: At week 24 and At week 52 ]
    EES included all eligible patients who were treated in the study eye, untreated in the fellow eye, had baseline specular microscopy image in both eyes, and completed week 52 evaluation in both eyes and treatment with systemic anti-VEGF therapeutics



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria include but are not limited to:

  1. Men or women great than or equal to 50 years of age with unilateral neovascular AMD
  2. BCVA ETDRS letter score of 73 to 24 (20/40 to 20/320) in the study eye
  3. Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to AMD, including juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye
  4. The CNV area must be at least 50% of total lesion size
  5. Willing and able to comply with clinic visits and study-related procedures
  6. Provide signed informed consent
  7. Provide signed Health Insurance Portability and Accountability Act (HIPAA) authorization

Exclusion criteria include but are not limited to:

  1. Neovascular AMD in the fellow eye
  2. Corneal endothelial measures as judged by an independent reading center
  3. Any prior use of intraocular anti-VEGF treatment for neovascular AMD in either eye
  4. Structural damage to the center of the macula in the study eye that is likely to preclude improvement in BCVA following the resolution of macular edema
  5. History of cataract surgery, or other intraocular surgery in either eye, within 1 year of screening
  6. History of cataract surgery, or other intraocular surgery in either eye, within 1 year of screening, or yttrium aluminum garnet (YAG) Capsulotomy within 3 months of screening
  7. Contact lens wear in either eye within 6 months of screening
  8. History of angle closure glaucoma in either eye
  9. Intraocular laser therapy including selective laser trabeculoplasty (SLT), YAG, prophylactic peripheral iridotomy (PI) in either eye within 1 year of screening, or YAG Capsulotomy within 3 months of screening
  10. History of cataract surgery requiring an anterior chamber intraocular lens implant at any time in either eye
  11. Any prior ocular trauma (blunt or penetrating) in either eye
  12. Embedded corneal foreign body in either eye
  13. Evidence of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye
  14. Ocular media of insufficient quality to obtain fundus and OCT images in the study eye
  15. Any prior ocular inflammation/infection in either eye within 3 months of the screening visit
  16. Any prior use of amantadine
  17. Significant pre-retinal fibrosis involving the macula in the study eye (where, in the opinion of the investigator, the pre-retinal fibrosis is causing distortion or traction on the central macular region which may be limiting vision, or inducing retinal edema/thickening, beyond that due to underlying CNV)
  18. Intraocular pressure (IOP) greater than or equal to 30 mm Hg in the study eye at screening
  19. Uncontrolled diabetes mellitus (DM) (HbA1c ≥8)
  20. Current treatment with systemic anti-VEGF therapeutics at screening
  21. Known serious allergy to the fluorescein sodium for injection in angiography
  22. Participation in an investigational study within 30 days prior to the screening visit that involved treatment with any drug (excluding vitamins and minerals) or device.
  23. Positive serum hCG pregnancy test at the screening visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01722045


  Show 49 Study Locations
Sponsors and Collaborators
Regeneron Pharmaceuticals
Investigators
Study Director: Clinical Trial Management Regeneron Pharmaceuticals

Responsible Party: Regeneron Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01722045     History of Changes
Other Study ID Numbers: VGFTe-AMD-1124
First Posted: November 6, 2012    Key Record Dates
Results First Posted: December 22, 2017
Last Update Posted: December 22, 2017
Last Verified: November 2017

Keywords provided by Regeneron Pharmaceuticals:
AMD

Additional relevant MeSH terms:
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases